Autolus Therapeutics plc logo
Autolus Therapeutics plc AUTL
$ 1.39 -1.42%

Annual report 2025
added 03-27-2026

report update icon

Autolus Therapeutics plc Financial Statements 2011-2026 | AUTL

Annual Financial Statements Autolus Therapeutics plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

322 M 424 M 1.09 B 299 M 270 M 332 M 352 M 1.08 B 43.4 M - - - - - -

Shares

266 M 255 M 174 M 95 M 72.1 M 51.6 M 43.1 M 39.4 M 13.8 M - - - - - -

Historical Prices

1.21 1.66 6.25 3.15 3.74 6.44 8.18 27.4 - - - - - - -

Net Income

-288 M -221 M -208 M -149 M -142 M -142 M -124 M -20.6 M -19.7 M -12.6 M - - - - -

Revenue

75.4 M 10.1 M - - - 242 K 2.91 M 1.41 M 1.69 M 1.21 M - - - - -

Cost of Revenue

96.4 M 11.4 M - - - - - - - - - - - - -

Operating Income

-271 M -241 M -180 M -143 M -141 M -168 M -146 M -25 M -23.4 M - - - - - -

Interest Expense

36.7 M 9.29 M 45.1 M 8.9 M 1.1 M 1.35 M 4.51 M 1.1 M -46 K -26 K - - - - -

EBITDA

-262 M -234 M -173 M -136 M -133 M -162 M -141 M -23.3 M -22.4 M -13.9 M - - - - -

Operating Expenses

- - - - - - 145 M 58.9 M 25.1 M 15.6 M - - - - -

General and Administrative Expenses

132 M 102 M 46.7 M 31.9 M 31.9 M 35 M 39.5 M 22.8 M 9.1 M 5.15 M - - - - -

All numbers in USD currency

Quarterly Income Statement Autolus Therapeutics plc

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

266 M 266 M 266 M 266 M 266 M 222 M 174 M 174 M 174 M - 91.2 M - - - - - 62.4 M - 52.1 M 52 M 49.9 M - 44.5 M 43.6 M 39.5 M 39.4 M 39.2 M 29.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-79.1 M -47.9 M -70.2 M -82.1 M -58.3 M -52.7 M -45.8 M -45.6 M -39.8 M - -42.8 M - - - - - -33.3 M - -37.3 M -32 M -29.9 M - -27.2 M -28.5 M -27.2 M -20.6 M -12.9 M -7.65 M -16.7 M -7.52 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

21.2 M 20.9 M 8.98 M - - 10.1 M - - - - - - - - - - 269 K - - 293 K 338 K - 297 K 338 K 1.96 M 296 K 307 K 443 K - 231 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

28.6 M 24.4 M 18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-71.6 M -61.2 M -65.2 M -67.9 M -58.9 M -38.8 M -42.9 M -44.4 M -39.1 M - -43.5 M - - - - - -39.9 M - -42.7 M -39.5 M -38.6 M - -35.6 M -37.2 M -30.2 M -25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

10.5 M -6.83 M 10.1 M 10.7 M 10.2 M 19.3 M 5.01 M 5.02 M 4.9 M - 1.85 M - - - - - 838 K - -2.51 M 525 K 4.48 M - 3.26 M 4.38 M -984 K 1.1 M - - - -685 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-69.5 M -59.1 M -63.2 M -66 M -57 M -37 M -41.5 M -42.9 M -37.2 M - -41.7 M - - - - - -38.2 M - -41.2 M -38.3 M -37.3 M - -34.5 M -36.1 M -28.5 M -24.4 M 300 K 500 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - 35.6 M 37.2 M - 25 M 17.1 M 16.5 M - 8.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

36.3 M 30.3 M 29.5 M 27.3 M 21.9 M 18.2 M 10.6 M 11.1 M 9.28 M - 8.23 M - - - - - 8.74 M - 9.84 M 8.51 M 7.61 M - 8.6 M 11.4 M 9.56 M 7.59 M 7.27 M 8.1 M - 3.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Autolus Therapeutics plc AUTL
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Autolus Therapeutics plc plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.54 -20.81 % $ 238 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.79 1.22 % $ 27.9 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
argenx SE argenx SE
ARGX
$ 748.25 0.25 % $ 25 B niderlandNiderland
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.89 -4.33 % $ 4.85 M chinaChina
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AbbVie AbbVie
ABBV
$ 206.69 -1.01 % $ 366 B usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.39 -3.69 % $ 1.01 B canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 5.97 0.51 % $ 1.44 B usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.75 0.91 % $ 17.6 B danmarkDanmark
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.23 -0.12 % $ 6.83 B spainSpain
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.32 -4.35 % $ 339 M usaUSA